Phase IIa Study of AV411, a Glial Activation Inhibitor, for Opioid Withdrawal
Status:
Completed
Trial end date:
2012-06-01
Target enrollment:
Participant gender:
Summary
Repeated use and/or abuse of opioid medications is generally associated with a characteristic
withdrawal syndrome that develops after cessation of drug administration. The present study
is designed to evaluate the effectiveness of AV411 to alter opioid-induced withdrawal
symptoms.